CRBU — Caribou Biosciences Inc
NASDAQ · Healthcare · Biotechnology
$1.58
+$0.03 (+1.73%)
Caribou Biosciences Inc (CRBU) is a biotechnology company listed on NASDAQ. It is led by Rachel E. Haurwitz Ph.D., based in 2929 7th Street, Berkeley, CA, United States, 94710, with about 97 employees. Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Latest reported CRBU revenue for 2025-09-30 was $2.2M. Net income was -$121.6M. Revenue was down 17.6% from 2025-06-30 to 2025-09-30. CRBU currently screens at market cap $190.4M.
Use this CRBU page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CRBU quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CRBU SEC filings page. Lician reads the product cache first so this HTML stays unique to Caribou Biosciences Inc even when a live quote feed is slow.
About Caribou Biosciences Inc
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
CRBU Key Statistics
Market Cap
$190.43M
Volume
1.38M
Previous Close
$1.64
Day Range
$1.65 – $1.76
EPS
-$1.65
Revenue
$9.99M
Net Income
-$149.10M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-71.0%
Profit Margin
-1491.9%
Employees
97
CRBU Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $9.99M | $34.48M | $13.85M | $2.56M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$149.10M | -$102.07M | -$99.42M | -$66.92M |
| EPS (Diluted) | -$1.65 | -$1.38 | -$1.64 | -$2.11 |
Total Assets
$313.31M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$16.29M
Operating Cash Flow
-$138.20M
Free Cash Flow
$0.00
Caribou Biosciences Inc Company Information
- Co-Founder, CEO, President & Director
- Rachel E. Haurwitz Ph.D.
- Headquarters
- 2929 7th Street, Berkeley, CA, United States, 94710
- Website
- cariboubio.com
- Phone
- 510 982 6030
- IPO / Founded
- 2021-07-23
- Sector
- Healthcare
- Industry
- Biotechnology